It takes a lot to surprise me these days in the cell therapy and regenerative medicine space, but some news from Walgreens stopped me in my tracks yesterday. The firm most well known for its drug stores and pharmacies has been struggling recently. Perhaps as a way to try to turn things around, they recently […]
New Walgreens shopping list: q-tips, aspirin, & cutting-edge gene & cell therapies Read More »
Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
I’m kind of in grant writing hell at the moment, as many of you may have been at various times, but I’m still finding time to read a little on cell therapy and stem cell research. Here are some things that caught my eye as I work on multiple grants with impending deadlines. Clinical trials
Weekly reads: cell therapy trials, melanoma, β-thalassemia Read More »
It’s mostly been a week of good and encouraging news in the regenerative medicine space including with gene therapies maybe with the exception of some eye drops warnings (more below). There’s realistic hope for an approved sickle cell disease soon. I also see some long-term positive news on hearing loss research. Hematopoietic stem cell transplant
Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell Read More »
I wrote earlier this week about genome sequencing of famous dead celebrities, pointing out that the trend seems full of ethical complexities. Genome news More broadly, sequencing the genomes of non-celebrities from hundreds or thousands of years ago can be important research. A new NYT piece covers such work on the Swahili people. Such research
Weekly reads: genome sequencing, chemical reprogramming 2.0 Read More »
It’s always exciting when your lab has a new paper and my team just published a study knocking out the H3f3a gene in mice, which codes for histone H3.3 protein. We found that loss of this gene leads to lethality at a late stage of embryonic development. There were also indications of more specific phenotypes
Weekly reads: H3.3 on the brain, Texas bill, HSCs Read More »
Out of the blue this past week we lost Kevin McCormack of CIRM to a heart attack. When I first heard, my reaction was that can’t be, but it is. About Kevin McCormack If you aren’t familiar with him, Kevin was officially Director of Patient Advocacy at our state’s Stem Cell Agency. However, he was
Weekly reads: Kevin McCormack passes, HSCs & RXR, Ethics Read More »
As I’ve mentioned recently, it’s my busy time for medical school teaching and not long ago we did a GI lab that included one of my favorite structures in the course: taste buds. Taste buds The medical students seem fascinated with taste buds too. I can tell as their professor when something is particularly interesting
Weekly reads: taste buds, organoids, good news on CRISPR safety Read More »
David Weinberg over at Science-Based Medicine has his part two of a deep dive into the so-called SCOTS trial, which is a non-traditional pay-for-play study. I highly recommend it. SCOTS trial under the magnifying glass In this piece, Weinberg provides interesting background on the two people running SCOTS. I’ve had many concerns about the SCOTS
Recommended reads: engineered niche, ALS, SCOTS trial, human genome “done” Read More »
It’s very challenging to be an academic scientist even under normal circumstances so when a government starts going after researchers for things like supposed irregularities in funding disclosures, it can cause serious problems if not carefully overseen. We’ll start this week’s recommended reads with the feds monitoring such disclosures and even making referrals to the
Weekly reads: Yale scientist suspended, WA AG sues clinic, new pubs Read More »